Trials / Recruiting
RecruitingNCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retatrutide | Administered SC |
Timeline
- Start date
- 2026-01-24
- Primary completion
- 2028-10-01
- Completion
- 2028-11-01
- First posted
- 2026-01-22
- Last updated
- 2026-04-17
Locations
35 sites across 3 countries: United States, Argentina, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07357415. Inclusion in this directory is not an endorsement.